- Home
- INSM vs INIO Comparison
INSM vs INIO Comparison
Compare INSM & INIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSM | INIO |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4B | 26.0B |
| IPO Year | 2000 | 2026 |
Fundamental Metrics
Financial Performance| Metric | INSM | INIO |
|---|---|---|
| Price | $118.52 | $20.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 24 | 0 |
| Target Price | ★ $201.17 | N/A |
| AVG Volume (30 Days) | 2.9M | ★ 3.8M |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $182.31 | N/A |
| Revenue Next Year | $65.19 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $90.39 | $21.69 |
| 52 Week High | $212.75 | $42.95 |
Technical Indicators
Market Signals| Indicator | INSM | INIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 35.27 |
| Support Level | $97.66 | $21.73 |
| Resistance Level | $119.54 | $30.09 |
| Average True Range (ATR) | 4.08 | 1.45 |
| MACD | -1.32 | -0.10 |
| Stochastic Oscillator | 2.22 | 4.89 |
Price Performance
Historical ComparisonAbout INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.